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Abstract
Background: Statins are shown to have cholesterol-independent properties such
as anti-inﬂammation and immunomodulation. Activated hepatic stellate cells
(HSCs) acquire the capacity to synthesize matrix proteins in damaged liver. We
tested the hypothesis that atorvastatin may be capable of inducing apoptosis
in HSCs. Methods: Primary cultures of rat HSCs were exposed to atorvastatin,
mevalonic acid and U0126. Quantiﬁcation of living, apoptotic and necrotic HSCs
was performed by ﬂow cytometry and laser-scan microscopy. Cell-cycle analysis
was performed by ﬂow cytometry. Pro- and anti-apoptotic factors were investi-
gated by Western blot and electrophoresis mobility shift assay. Protease activity of
caspases was calculated using a colorimetric kit. Results: Atorvastatin leads to a
G2-arrest and induces apoptosis in activated HSCs. Atorvastatin-mediated apop-
tosis could be blocked by co-administration of mevalonic acid and U0126. No
effects of atorvastatin on gene expression of CD95, CD95L, NF-kB, p53 and
p21WAF1 could be observed. Atorvastatin-induced apoptosis in activated HSCs is
related to an increased protease activityof caspase-9 and -3. Gene expression of the
major proteins of the bcl-system shows that truncated Bid is involved in apoptosis
mediated by atorvastatin. By blocking the extracellular signal-regulated
protein kinase (ERK1/2) activation by adding U0126, we could prevent the
apoptosis induced by atorvastatin. By Western blot we could not detect any
change in the activation of c-jun N-terminal kinase (JNK). Conclusions:
Atorvastatin induces apoptosis in activated HSCs acting through an ERK-
dependent cleavage of Bid and a highly increased protease activity of caspase-9
and -3. JNK is not involved in atorvastatin-mediated apoptosis in HSCs.
Hepatic stellate cells (HSCs) are one of the mesenchy-
mal cell populations involved in liver ﬁbrosis and may
becomethemain actorincertain formsofcirrhosislike
haemochromatosis (1) or alcoholic cirrhosis (2). Liver
ﬁbrosis canbeclassiﬁedas awound healingresponseto
a variety of chronic stimuli that is characterized by an
excessive deposition of extracellular matrix (ECM), of
which type I and type III collagen predominate. At
present, liver ﬁbrogenesis is considered a dynamic
process involving complex cellular and molecular me-
chanisms, resulting from the chronic activation of the
tissue repair mechanisms, which follows recurring liver
tissue injury. If the chronic damage persists, inﬂamma-
tion and ﬁbrosis can progress to liver cirrhosis, ulti-
mately leading to organ failure and death. During
recovery from liver ﬁbrosis in the rat carbon tetra-
chloride or in the bile duct ligation model, there is a
reduction in the number of a-smooth muscle actin
(SMA)-positive cells. Further ﬁndings strongly sug-
gested that apoptosis of activated HSCs is responsible
for mediating cell loss during recovery from ﬁbrosis
(3–6). Evolving antiﬁbrotic therapies should therefore
focus on treatments of activated HSCs.
3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-
CoA) reductase inhibitors, or statins, are widely used
in the clinic for their cholesterol-lowering properties.
Re-use of this article is permitted in accordance with the Creative
Commons Deed, Attribution 2.5, which does not permit commercial
exploitation.
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Liver International ISSN 1478-3223Although the beneﬁts of lowering cholesterol levels in
the prevention and treatment of cardiovascular dis-
eases are proven, several clinical trials have shown that
statins also have cholesterol-independent properties
(7–14), including improving endothelial function
(15–18), enhancing plaque stability (19, 20), decreas-
ing vascular inﬂammation and oxidative stress, inhi-
biting the thrombogenic response in the vascular wall,
and immunomodulatory properties by inhibiting ex-
pression of MHC class II proteins (21). These ‘pleio-
tropic’ effects can be attenuated by addition of the
postreductase product, mevalonate (22), and are re-
lated to inhibition of the production of other isopre-
noids such as farnesylpyrophosphate (FPP) and
geranylgeranylpyrophosphate (GGPP) (23).
Although the impact of statin therapy on each of
these processes is not fully understood, ongoing stu-
dies are likely to shed further light on the potential
pleiotropic beneﬁts of statins, some of which are
focusing on ECM-producing cells to evaluate a poten-
tial antiﬁbrogenic effect. An in vitro study on rat HSCs
treated with two different statins showed that the
collagen synthesis by activated cells was decreased
(24). To establish whether this effect could be because
of a reduction of cellular viability through the induc-
tion of apoptosis, we studied the effect of one of the
statins of the newest generation, atorvastatin, on
the cellular life of rat HSCs.
Material and methods
Hepatic stellate cell isolation, characterization,
plating and culture conditions
Wistar rats were provided by Charles River (Sulzfeld,
Germany) and maintained under 12:12-h light/dark
cycles with food and water ad libitum. In conducting
the research described in this report, all animals
received humane care in compliance with the institu-
tion’s guidelines and the National Institute of Health
(NIH) Guidelines. HSCs were isolated by sequential
in situ perfusion with collagenase and pronase, as pre-
viously described (25). A mean of 4010
6 HSCs were
obtained per rat. Cells were plated onto 24-well Falcon
plates (Becton Dickinson, Heidelberg, Germany), 35mm
Petri dishes (Greiner, Krefeld, Germany), 96-well Falcon
plates (Becton Dickinson) and Lab Tek tissue culture
slides (Nunc, Naperville, IL, USA) with a density of
30000cells/cm
2. Cells were cultured in Dulbecco’s mod-
iﬁed Eagle’s medium supplemented with 10% foetal calf
serum (FCS), 100U/ml penicillin, 100mg/ml streptomy-
cin and 1% L-glutamine. Culture mediumwas replaced at
day 2 after plating and then every other day. Cells were
kept in culture at 371Ci na5 %C O 2 atmosphere and
100% humidity.
To evaluate the purity of the cultures, HSCs were
tested by immunoﬂuorescence at day 0, day 2 (quies-
cent/early activated HSC) and day 7 (activated HSC)
after plating as described previously. Contamination
with Kupffer cells (ED1 positive) was o2%, and
neither endothelial cells nor hepatocytes were detected
(26–31). With the use of SMA immunoreactivity as an
activation parameter (32), HSCs were fully activated
after 7 days of primary culture (100% SMA positive).
Fibulin-2-positive cells (liver myoﬁbroblasts) were
always o1% (33, 34). HSCs at days 2, 4 and 7 of
primary culture were washed two times with Gey’s
balanced salt solution and incubated for 20h in
serum-reduced (0.3% FCS) culture medium alone or
in the presence of atorvastatin (10
3,1 0
5,1 0
7,1 0
9,
10
11mol/L) and/or mevalonic acid (125mM) as well
as U0126 (10mM).
Cell-cycle analysis
510
5cells in 200mlC a
21,M g
21-free phosphate-buf-
fered saline were ﬁxed in 4ml 70% ethanol/30% phos-
phate-buffered saline at 01C, digested with 1000U
RNAse A (Sigma-Aldrich, St Louis, MO, USA), and
stained with 1% propidium iodide at 371C for 30min.
The DNA proﬁles were determined within 4h of stain-
ing by ﬂow cytometry (EPICS ML, Coulter, Kerfeld,
Germany) (35). Data were analysed using the program
MULTICYCLE for Windows Ver. 3.0 (Phoenix Flow Systems,
San Diego, CA, USA).
Flow cytometric quantiﬁcation of living, apoptotic
and necrotic hepatic stellate cells
To quantify apoptotic cells, ﬂow cytometry was used
after trypsination of the HSCs (EPICS ML, Coulter). To
detect early apoptotic changes, staining with annexin
V–ﬂuorescein isothiocyanate (FITC) was used, because
of its known high afﬁnity to phosphatidylserine (36).
Phosphatidylserine is normally situated on the inner
l e a ﬂ e to ft h ep l a s m am e m b r a n e .I nt h ec o u r s eo fc e l l
death, phosphatidylserine is translocated to the outer
layer of the membrane (37) (i.e. the external surface of
the cell). This occurs in the early phases of apoptosis,
while the cell membrane itself remains intact. In contrast
to apoptosis, necrosis is accompanied by loss of cell
membrane integrity and leakage of cellular constituents
into the environment. To distinguish apoptosis and
necrosis, propidium iodide, a common dye exclusion
test, and annexin V–FITC were used in parallel to show
membrane integrity after annexin V–FITC binding to
cells. In all investigated cases, no loss of membrane
Liver International (2008)
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V–FITC binding was detected.
The ﬂuorescence from endogenous vitamin A was
digitally removed using unstained cell samples as
negative controls. In addition, we performeda staining
with Tdt-mediated X-dUTP nick-end labelling (TU-
NEL) according to the protocol of the manufacturer
(Boehringer, Mannheim, Germany) evaluated using
confocal microscopy.
Confocal laser scan microscopic detection of
apoptosis in activated hepatic stellate cells using the
mitochondrial membrane sensor kit
To investigate induction of apoptosis, blocking apoptosis
and apoptosis occurring spontaneously at days 2 and 7,
we performed a test using confocal laser scan microscopy
(Zeiss, Oberkochen, Germany) in the time-scan mode.
HSCs at the seventh day (d7) after plating were incu-
bated for 8 and 20h in reduced serum medium with
atorvastatin, with and without mevalonate, with meva-
lonate (125mM) alone, with or without U0126 and with
U0126 alone (10mM). Control wells were left untreated.
Apoptosis was detected using the ApoAlert Mitochon-
drial Membrane Sensor Kit (BD Biosciences, Clonthec,
San Jose, CA, USA). This is a ﬂuorescence-based assay
where the dye is able to accumulate in the intact
mitochondria. In case of apoptosis, it aggregates in the
cytosol and alters the ﬂuorescence colour. By this change
in the ﬂuorescence colour it is possible to discriminate
between apoptotic (green) and living (red) cells.
Western blot analysis
Cells on different days after plating were lysed in hot
Laemmli buffer (951C )a n dp r o c e s s e db ys o d i u md o d e -
cyl sulphate-polyacrilamide gel electrophoresis under
reducing conditions according to Laemmli (38). The
protein content of cellular lysates was calculated using
the Coomassie Protein Assay (Pierce, Rockford, IL,
USA); b-actinwas used as loading control. Proteins were
transferred onto Hybond-ECL nitrocellulose hybridiza-
tion transfer membranes according to Towbin et al.( 3 9 ) .
Immunodetection was performed according to the ECL
Western blotting protocol. Primary antibodies were used
at a 1:200 dilution. Anti-mouse and anti-rabbit immu-
noglobulins were each used at a 1/1000 dilution. Densi-
tometric evaluation of the blots was performed using the
program SCION IMAGE Ver. Beta 2 (NIH).
Electrophoresis mobility shift assay
After appropriate treatment times, cells were trypsinized
and washed once with 1ml Tris-buffered saline
(20mmol/L) and Tris HCl (pH=7.2, 0.15mol/L NaCl).
Then cells were resuspended in 0.5ml extraction buffer
(10mmol/L HEPES pH=7.9, 10mmol/L KCl,
1.5mmol/L MgCl2, PMSF 1mmol/L) and incubated
for 15min on ice. This was followed by the addition of
30ml NP-40 and vortexing for 10s. The pellet was
harvested with a brief centrifugation and suspended in
50ml of the same extraction buffer containing 0.4mol/L
NaCl. Cell nuclear regulatory proteins were extracted
with vigorous agitation on ice for 15min. DNA was
pelletted with centrifugation (5min, 41C, 15000g). The
supernatant was taken for electrophoresis mobility shift
assay (EMSA) reaction. The protein concentration was
determined with Coomassie Assay (Pierce). The label-
ling was done with T4 polynucleotide kinase. This
enzyme cuts the last phosphate from adenosine tripho-
sphate (ATP) and links it to any polynucleotide: in our
case to p53 (Santa Cruz Biotech, Santa Cruz, CA, USA)
or to NF-kB-a (Promega, Madison, WI, USA) oligonu-
cleotides. EMSA (p53 and NF-kB) and supershift (NF-
kB) reactions were done in 20ml reaction mixture based
on the extraction buffer with NaCl containing 10mg
nuclear extract 105cpm labelled oligonucleotides and in
t h ec a s eo fs u p e r s h i f tw eu s e d4mgo fr a b b i tp o l y c l o n a l
antibody against the p65-NF-kB (Transcruz, Santa Cruz
Biotechnology). The binding reaction was performed
at 41C overnight. DNA–protein complexes were re-
solved by electrophoresis through a 4% polyacrilamide
gel containing 45mM TRIS-borate and 1mM ethylene
diamine tetraacetic acid (EDTA) at pH 8.0. Gel was
dried and exposed to X-ray ﬁlm overnight.
Colorimetric assay of the protease activity of
caspase-3, -8 and -9
Measurement was performed using a kit for each
caspase (Calbiochem-Novabiochem Corporation, San
Diego, CA, USA), in accordance with the manufac-
turer’s instructions. The kits work on the properties
of a colorimetric substrate which, when cut, increase
light absorption at 405nm. The kits contain a speciﬁc
inhibitor of the colorimetric substrate as a negative
control. For these experiments, cells were plated onto
96-well plates and analysed at day 7 after culture, after
treatment with atorvastatin and/or mevalonic acid
(125mM), with and without U0126 (10mM). Control
wells were left untreated.
Statistical analysis
Results are expressed as meanSD, and the signiﬁ-
cance of the difference between the means was assessed
by ANOVA followed by Bonferroni’s post-test.
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Effect of atorvastatin on the cell cycle of isolated rat
hepatic stellate cells
Primary isolated HSCs at the second day after plating
(d2) were used as a model for quiescent HSCs, while
cells at the d7 after plating were used as a model for
activated HSCs. In activated HSCs (d7) treated with
atorvastatin (10
9mol/L), there is an increase of cells
in phase G2 (from 613.2 to 754.1%, Po0.05)
while the percentage of cells in the S and G0/G1 phase
decreased (from 172.1 to 113.1% and from
212.7 to 141.8%, respectively, Po0.05). In
quiescent HSCs treated with atorvastatin, the percen-
tage of cells in the G0/G1 phase is strongly reduced
compared with the control (from 655.3 to
213.6%, Po0.01) while the percentage of cells in
the G2 phase increased (from 314.2 to 724.3%,
Po0.01). The percentage of cells in the S phase
remains unchanged (Fig. 1). The decrease of the
portion of cells being in the S phase of cell cycle could
also be shown by 3H-thymidine incorporation in both
quiescent and activated HSCs. The effects are dose
dependent and ﬁrst detectable after 20h.
Apoptosis detection in hepatic stellate cells
To investigate the fate of HSCs, we performed a study
using confocal laser scan microscopy and ﬂow cyto-
metry. In activated HSCs atorvastatin is capable of
inducing apoptosis, and this effect is dose dependent
(Fig. 2a) and ﬁrst detectable after 20h. At dosages with
physiological serum concentrations of the order
10
7–10
8mol/L (40), the fraction of cells undergoing
apoptosis increased in a dose-dependent manner from
a control value of 19 (spontaneous apoptosis) to 60%.
Increasing the dose of atorvastatin, the percentage of
apoptotic cells increases proportionally up to 92%
apoptosis (Po0.01) at a dose of 10
3mol/L atorvas-
tatin. At this time point, o2% of total cells were
detected as necrotic. Addition of mevalonate or cas-
pase-9 inhibitor as well as U0126 fully prevented the
apoptosis induced by atorvastatin (data not shown).
In quiescent HSCs, the fraction of cells undergoing
apoptosis at dosages with physiologic serum concen-
trations was not signiﬁcantly different from the con-
trol. At high concentrations (10
3 and 10
5mol/L) of
atorvastatin, the fraction of apoptotic cells increased
from a basal level of 4–10% (Fig. 2b). A toxic effect
measured as increased portion of necrotic cells could
not be observed.
Effect of atorvastatin on the expression of CD95,
CD95L, Bax, Bcl-xl, Bcl2, Bid, t-Bid, JNK, p-JNK,
ERK1/2 and p-ERK1/2, in isolated rat hepatic
stellate cells
The effects of atorvastatin on important members of
pro-apoptotic and anti-apoptotic pathways [CD95,
CD95L, Bcl-xl, Bcl-2, Bax, Bid, truncated Bid (t-Bid),
c-jun N-terminal kinase (JNK), phospho-JNK
(p-JNK), extracellular signal-regulated protein kinase
(ERK1/2) and phosphorylated-ERK1/2 (p-ERK1/2)]
were evaluated in quiescent and activated HSCs by
Western blot analysis (see Fig. 3). To establish if the
apoptotic effect of atorvastatin on HSC was mediated
by the CD95/CD95L pathway, we evaluated the ex-
pression of those proteins in quiescent and activated
HSCs, in control and in atorvastatin-treated cultures.
No changes in the cells treated with atorvastatin
compared with the control could be observed. These
results suggest that the CD95/CD95L system is not
involved in the apoptotic effect of atorvastatin in
activated HSCs. Under the same experimental
Fig. 1. Cell cycle analysis of hepatic stellate cells (HSCs) treated with atorvastatin. In quiescent HSCs the percentage of cells in the S
phase remains unchanged from the control. The percentage of cells treated with atorvastatin being in the G2 phase increased, while
the percentage of cells being in the G0/G1 phase was reduced. In activated HSCs treated with atorvastatin, the percentage of cells in
the S and in the G0/G1 phases decreased while an increase of the cells being in the G2 phase occurred. Values presented are mean
percentages of seven independent experiments. Values are means 1SD.
Liver International (2008)
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of atorvastatin was determined by a pro-apoptotic
ratio between the apoptosis-promoting (t-Bid, Bax)
andapoptosis-inhibiting (Bcl-2,Bcl-xl) memberof the
bcl system. While there is, as previously described, an
increased expression of Bax anda decreased expression
of Bcl-2 and Bcl-xl (pro-apoptotic ratio) in activated
HSCs compared with the quiescent HSCs, no signiﬁ-
cant changes between the control and the cells treated
with atorvastatin were detectable (Fig. 3A) other than
a decrease of Bid, and an increased occurence of t-Bid,
as well as of p-ERK1/2) in activated HSCs treated over
20h with atorvastatin. This effect could be blocked by
adding mevalonate and U0126 (Fig. 3B).
Effect of atorvastatin on the expression of NF-jB
and p53 in isolated rat hepatic stellate cells
Nuclear factor-kB and p53 are ubiquitous transcrip-
tion factors involved in the regulation of the apoptotic
process. While the upregulation of NF-kB acts on the
bcl system enhancing the expression of the apoptosis-
promoting members, the upregulation of the tran-
scription factor p53 promotes apoptosis by arresting
cells in phase G2 of the cellular cycle. The EMSA and
the Western blot analysis for NF-kB (Figs 4 and 5a)
and p53 (Figs 4 and 5b) show that, while their
expression is increased in activated HSC compared
with the quiescent cells, there are no differences in
gene expression between the control and cells treated
with atorvastatin.
Activity of caspase-8, -9 and -3
Caspase-3 is a member of the interleukin-1 a convert-
ing enzyme (ICE) family of cysteine proteases. It
is activated during apoptotic signalling events by
upstream proteases including caspase-8 (CD95/
CD95L-mediated pathway) and caspase-9 (mitochon-
drial pathway). Targets of caspase-3 cleavage include
poly(ADP-ribose) polymerase (PARP), six nuclear
lamins, seven and others that lead to DNA damage
and, if no repairing systems are activated, to apoptosis.
The protease activity of caspase-8, -9 and -3 was
measured in activated HSCs treated with atorvastatin,
with and without mevalonate, and in control. As
shown in Figure 6, in the cells treated with atorvasta-
tin, the activity of caspase-9 increased to 407%, and
the activity of caspase-3 to 540%, while there is no
change in the activity of caspase-8. Addition of meva-
lonate or U0126 fully prevented the atorvastatin-
induced increase of caspase-9 and -3 activity. This
demonstrates that the pro-apoptotic effect of atorvas-
tatin in HSC is speciﬁc and may be mediated by the
ERK-dependent mitochondrial pathway, with further
activation of the caspase-9 cascade.
Apoptosis detection using the mitochondrial
membrane sensor kit
To prove that the activation of caspase-9 follows the
mitochondrial pathway of apoptosis, we performed a
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Fig. 2. Detection of apoptosis induced by atorvastatin on
quiescent hepatic stellate cells (HSCs). HSCs at days 2 and 7 of
primary culture were incubated for 20h in serum-reduced
(0.3% foetal calf serum) culture medium alone or in the
presence of atorvastatin (10
3,1 0
5,1 0
7,1 0
9,1 0
11mol/L).
(A) In activated HSCs (day 7), the percentage of cells undergoing
apoptosis increased proportionally from a control value of 19%
apoptosis (spontaneous apoptosis) with increasing doses of
atorvastatin to 60% at physiological serum concentrations (10
7
and 10
8mol/L) and to 92% apoptosis at a dosage of 10
3mol/L
atorvastatin. (B) The effects of atorvastatin on quiescent HSCs
(day 2)was not signiﬁcant at physiological serum even though at
higherconcentrations (10
5 and 10
3mol/L), the fraction of cells
in apoptosis increased from a basal level of 4–10%. Data were
obtained by ﬂuorescent-activated cell sorting analysis of cells
stained with annexin V–ﬂuorescein isothiocyanate and
propidium iodide. Values presented are mean percentages of
seven independent experiments. Values are meansSD. Level
of signiﬁcance: Po0.05; Po0.01.
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changes that occur in the mitochondrial membrane
potential during apoptosis. The data obtained in
quiescent and activated HSCs treated with atorvasta-
tin, with and without mevalonic acid, mevalonic acid
alone and in control, conﬁrm the data obtained
by ﬂuorescent-activated cell sorting. In addition,
apoptosis occurring in activated HSCs at the mito-
chondrial level could be detected 8h after administra-
tion of atorvastatin, whereas ﬁrst apoptotic changes at
nuclear level (TUNEL positivity) occurred after 20h.
The complete prevention of the atorvastatin-induced
apoptosis by mevalonic acid demonstrates that this
effect is speciﬁc (Fig. 7).
Discussion
In this work we studied the effect of atorvastatin on
cell cycle and on the fate of activated rat liver HSCs in
primary culture. Atorvastatin dose dependently in-
duces a G2 arrest and an apoptosis rate of 68% at
‘therapeutic’ concentrations in activated HSCs. The
apoptotic effect is mediated by the ERK-dependent
mitochondrial pathway followed by the increase of
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Fig. 3. Western blot analysis of Bcl-xl, Bcl-2, Bax, truncated Bid (t-Bid), c-jun N-terminal kinase (JNK), phospho-JNK (p-JNK),
extracellular signal-regulated protein kinase (ERK1/2), phospho-ERK1/2 (p-ERK1/2), CD95 and CD95L. (A) Sodium dodecyl sulphate-
polyacrilamide gel electrophoresis of HSC cell lysates at days 2 and 7 of control cultures and cultures treated over 6 and 20h with
atorvastatin 10
7mol/L, with and without U0126. Densitometry was performed for the different lanes and normalized on the
repective b-actin loading control. Values for the controls at day 2 were set as 100%. (A). An increased expression of Bax and a
decreased expression of Bcl-2 and Bcl-xl (pro-apoptotic ratio) in activated hepatic stellate cells (HSCs) compared with the quiescent
HSCs were detected. However, no signiﬁcant changes between the control and the cells treated with atorvastatin were noted. In
activated HSCs compared with the quiescent cells, a strongly increased expression of CD95 and a signiﬁcantly increased expression of
CD95L were obtained; however, no changes between the control cells and the cells treated with atorvastatin were noted. (B) On the
other hand an increased portion of p-ERK1/2 and t-Bid but not of p-JNK in activated HSCs treated over 20h with atorvastatin could be
observed. This effect could be blocked by adding ERK1/2 inhibitor U0126 as well as by adding mevalonate. We could conﬁrm the data
in ﬁve different blots of ﬁve independent experiments.
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Aprigliano et al. Inﬂuence of atorvastatin on apoptosis and proliferation of HSCFig. 4. Western blot analysis of nuclear factor (NF)-kB and p53.
Sodium dodecyl sulphate–polyacrilamide gel electrophoresis of
hepatic stellate cell (HSC) cell lysates at days 2 and 7 of control
and atorvastatin 10
7mol/L. While is possible to detect an
increased expression of both nuclear factors in activated HSCs
compared with the control, changes between control cells and
the cells treated with atorvastatin are not detectable. We could
conﬁrm the data in ﬁve different blots of ﬁve independent
experiments.
Fig. 5. Electrophoretic mobility shift assay to assess nuclear factor (NF)-kB (Fig. 5a, Supershift) and p53 (Fig. 5b) DNA binding activity.
Nuclear extracts of hepatic stellate cells (HSCs) at days 2 and 7 in control and in atorvastatin 10
7mol/L were assessed using a NF-kB
and p53 binding site as probe. Please note that in both quiescent and activated HSC, there are no differences between the control and
the cells treated with atorvastatin. We could conﬁrm the data in ﬁve different blots of ﬁve independent experiments.
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410
6 activated hepatic stellate cells (HSCs) after 20h
incubation with serum-reduced medium control, with
atorvastatin 10
7mol/L, with mevalonic acid 125mmol, with
caspase-9 inhibitors and with atorvastatin and mevalonic acid.
Values for HSCs control were set at 100%. In cells treated with
atorvastatin, the activity of caspase-9 increased to 407% and
the activity of caspase-3 increased to 540%, while in cells
treated with mevalonic acid, caspase-9 inhibitors and where
mevalonic acid was added to atorvastatin, there were no
signiﬁcant differences to the control. The activity of caspase-8
remained unchanged. We could conﬁrm the data in ﬁve
independent experiments. Values are meansSD. Level of
signiﬁcance: Po0.05; Po0.01.
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caspase-9 inhibitors, by ERK-inhibitor U0126 as well
as by mevalonic acid.
The HMG-CoA reductase inhibitors are widely used
in clinics for their cholesterol-lowering properties.
Recent experimental and clinical evidence indicates
that some of the beneﬁcial effects of statins are because
of their pleiotropic effects, such as anti-inﬂammation
and immunomodulation, encouraging further re-
search aimed at evaluating the potential of statins
(7–21, 23).
Activated HSCs are one of the major matrix-produ-
cing cell types during liver repair and ﬁbrosis. During
recovery from liver ﬁbrosis in the rat carbon tetra-
chloride and bile duct ligation model of ﬁbrosis, there
is a reduction in a-SMA-positive cell number. Further
ﬁndings strongly suggested that apoptosis of activated
HSCs may be responsible for mediating cell loss
during recovery from ﬁbrosis (3–6). Evolving antiﬁ-
brotic therapies are therefore targeted at inhibiting
activation of HSCs or in inducing their apoptosis.
In a previous in vitro study, the effects of two
different HMG-CoA inhibitors (simvastatin and lo-
vastatin) on rat HSCs were evaluated. The results show
that these statins are able to reverse the activation and
to inhibit the synthesis of collagen type I and reduce
the synthesis of collagen types III and IV. These effects
were partially reversible with PDGF and mevalonate
(24). We believe that these effects are due to apoptosis
induced by statins.
In this study we have shown that atorvastatin, one
of the statins of the newest generation, is capable of
blocking activated HSCs in the G2 phase of the cellular
cycle and of inducing their apoptosis in vitro. The
apoptosis induced by atorvastatin is dose dependent
in activated HSCs. The fraction of cells undergoing
apoptosis increased from a control value of 19%
apoptosis (spontaneous apoptosis) proportionally
with increasing doses of atorvastatin to 60% at the
serum concentration used in clinic (10
7–10
8mol/L)
and to 92% apoptosis at a dose of 10
3mol/L atorvas-
tatin. In quiescent HSCs, the fraction of cells under-
going apoptosis at the serum concentration used in
clinics, does not differ signiﬁcantly from the control.
However, at the dosage used in clinic the concentra-
tion of atorvastatin in the tissue remains unknown;
nevertheless no toxic effect and no changes at the
mitochondrial level could be detected in quiescent
HSCs even at higher dosage (10
3 and 10
5mol/L).
These data suggest that atorvastatin, by up-regulat-
ingthe apoptosisof activated HSCs, could decreasethe
extent of ﬁbrosis in chronic liver injury while having
no effects on quiescent HSCs. Induction and execution
of apoptosis programmes are generally believed to be
mediated through a hierarchy of caspase activation.
Caspases are synthesized as catalytically inactive pro-
Fig. 7. Laser scan microscopy detection of apoptosis in activated
hepatic stellate cells (HSCs) by the ApoAlert Mitochondrial
Membrane Sensor Kit. At days 2 or 7 of primary culture, cells were
incubated for 8h in serum-reduced (0.3% foetal calf serum) culture
medium alone, with atorvastatin 10
7mol/L, with mevalonic acid
125mM or with atorvastatin and mevalonic acid. Activated HSCs
(d7) treated with atorvastatin, unlike the control and the cells where
mevalonate were added, were exhibiting an increase in the green
ﬂuorescence owing to the apoptotic changes in the mitochondria.
This effect could be inhibited by coadministration of mevalonate. In
quiescent HSCs (d2) no signiﬁcant changes in the ﬂuorescence
could be detected among the differently treated cells. We could
conﬁrm the data in ﬁve independent experiments.
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cleavage at internal aspartate residues (41, 42). Two
pathways of caspase activation during apoptosis have
been described. The ﬁrst one is mediated by death
receptors, such as CD95 or tumour necrosis factor
(TNF) receptors, controlledbycaspases-8/10, which in
turn activate downstream effector caspases such as
caspase-3 and -7. Spontaneous apoptosis occurring in
activated HSCs involves an increased expression of
CD95/CD95L (Fas and Fas-ligand) (3).
We evaluated the expression of those proteins in
control and in atorvastatin-treated cultures. Although
a strong increase in the expression of CD95 and a
signiﬁcant increase in the expression of CD95L were
noted in activated HSCs compared with the control
cells, no signiﬁcant changes between the control cells
and the cells treated with atorvastatin were detectable,
showing that the CD95/CD95L pathway is not in-
volved in the apoptosis induced by atorvastatin. In the
second pathway, diverse apoptotic signals converge at
the mitochondrial level, inducing the release of cyto-
chrome C from the mitochondria to the cytosol (the
cytochrome C is being released into the cytoplasm
following the loss of the mitochondrial transmem-
brane potential) (43, 44). Once in the cytosol, cyto-
chrome C binds to its cytosolic partner apoptotic
protease activating factor-1 (APAF-1) and induces the
oligomerization of APAF-1–cytochrome C complex in
a dATP/ATP-dependent manner (45, 46). This multi-
meric complex, named ‘apoptosome’, is sufﬁcient to
recruit the initiator caspase, procaspase-9, to the
complex and induces procaspase-9 autoactivation
(47). The activated caspase-9 is released from the
apoptosome and subsequently initiates a caspase cas-
cade involving effector caspases such as caspase-3, -6
and -7 (48, 49).
Once active, these caspases cleave various cellular
targets, ultimately leading to cell death. It is known
that both the death receptor and the mitochondrial
pathway can be interconnected via the activation of
the pro-apoptotic Bcl-2 family member, Bid, through
caspase-8, possibly serving as an ampliﬁcation loop
(50). The mitochondrial pathway of caspase activation
is largely determined by the Bcl-2 family of anti- and
pro-apoptotic regulators. These proteins respond to
cues from various forms of intracellular stress, such as
DNA damage or cytokine deprivation, and interact
with opposing family members to determine whether
or not the caspase proteolytic cascade should be
unleashed (51). Some Bcl-2 family members that are
located on the mitochondrial membrane can alter the
permeability of the mitochondrial membrane and
trigger the activation of caspases. Bid is distinguished
from other pro-apoptotic Bcl-2 family members in
that it plays a critical role in both receptor- and
granule-mediated apoptosis because Bid is a substrate
for both active caspase-8 and granzyme B. Active
caspase-8 cleaves Bid at aspartic acid residue 60, while
granzyme B preferentially cleaves Bid as aspartic acid
residue 76. The cleavage product as processed by either
protease, termed t-Bid, then translocates to the mito-
chondria through mechanisms that include selective
binding to cardiolipin, a mitochondrial membrane
lipid. Once at the mitochondria, t-Bid induces the
oligomerization of Bax and Bak, leading to mitochon-
drial membrane permeability and release of the apop-
tosome, which activates caspase 9.
We have previously shown that the ERK-dependent
activation of the Bcl-2 family can have a pro-apoptotic
effect on HSCs (52).
The mitogen-activated protein (MAP) kinases are a
familyofsecond-messengerkinasesthatareessentialfor
transferring signals from the cell surface to the nucleus.
These kinases are a family of serine–threonine
protein kinases that are activated in response to a
variety of extracellular stimuli. ERK, c-Jun NH1-
terminal kinase (JNK) and p38 MAP kinase constitute
three major subfamilies of MAP kinases that appear to
mediate cellular responses, including proliferation,
differentiation and apoptosis. (53)
Extracellular signal-regulated protein kinase plays a
major role in cell proliferation and differentiation, as well
as in survival mediated by various growth factors (54).
On the other hand, JNK and p38 MAP kinase are
activated by various inﬂammatory cytokines and en-
vironmental stressors, and play an important role in
the signal cascades leading to the induction of cyto-
kines and chemical mediators (55).
Cellular ERK activation either inhibits or enhances
apoptosis in some cells (56, 57). Even in the same cell,
the role of ERK activation is likely to differ depending
on the cellular insult (56).
Several studies revealed a pathway of apoptosis
induced by an ERK-dependent increased activation of
the downstream kinases JNK and p38 MAP kinase. On
the other hand, other studies have shown that ERK-
induced apoptosis may occur with or without activa-
tion of JNK (58, 59).
In the present study we have shown the effect of
atorvastatin in leading to apoptosis in activated HSCs,
and we gained insight into mechanisms of apoptotic
response, previously undetected in HSCs.
When we evaluated the expression of some of the
pro- and anti-apoptotic members of the Bcl-2 family,
in quiescent and activated HSCs, in control and in
atorvastatin-treated cultures, the results showed an
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of Bcl-2 and Bcl-xl (pro-apoptotic ratio) in activated
HSCs compared with the quiescent HSCs. Between the
control cells and the cells treated with atorvastatin, we
could detect an activation of t-Bid in activated HSCs
treated over 6h with atorvastatin, but the activity of
caspase-8 remained unchanged, showing that there is
no link between the death receptor and the mitochon-
drial pathway. We followed the MAP kinase and the
caspase activation pathways; atorvastatin induces an
increased phosphorylation of ERK(1/2), but not its
basal expression level. By adding the ERK-inhibitor
U0126 and also by adding mevalonic acid to activated
HSCs, we could fully block the apoptosis induced
by atorvastatin. The increased phosphorylation of
ERK(1/2) is not followed by activation of JNK.
In this study we have shown that the pro-apoptotic
effect of atorvastatin on HSCs does not involve death
receptors such as Fas, while it seems to be mediated by
the release of cytochrome C from the mitochondria,
induced by an ERK-dependent activation of t-Bid,
followed by an increase in the activity of caspase-9
and -3 (Fig. 8).
In cells treated with atorvastatin, we could detect
apoptotic changes at the mitochondrial level 6h after
beginning the treatment, while the detection of apop-
tosis with other methods (annexin V-FITC, TUNEL)
was ﬁrst possible after 20h.
Apoptosis induced by atorvastatin in activated
HSCs in culture is fully inhibited by caspase-9 inhibi-
tors, ERK-inhibitor and mevalonate, showing that this
effect is speciﬁc.
We also evaluated the expression of the transcrip-
tion factors NF-kB and p53. Activation of NF-kBi n
cultured HSCs is required for expression of speciﬁc
genes associated with the activated phenotype and is
anti-apoptotic for rat HSCs, while the normal func-
tion of p53 is to effect cell cycle arrest at the G1 and G2
phases in response to DNA damage to allow DNA
repair and, if repair is not successful, p53 initiates
programmed cell death to prevent the propagation of
genetic defects to successive generations of cells. In-
volvement of those proteins in apoptosis regulation in
HSCs could be shown for the signals of transforming
growth factor (TGF)-a and TNF-a (60). Both tran-
scription factors areincreasinglyexpressed in activated
HSCs compared with quiescent cells, but no differ-
ences were detectable in atorvastatin-treated cells
compared with the control, showing that the increased
ERK1/2 phosphorylation and the apoptotic pathway
Apoptosis
Atorvastatin
Bid
ProCaspase-9
ERK 1/2 p-ERK 1/2
t-Bid
Cytochrome-C release from 
Mitochondria
Caspase-9
Caspase-3 ProCaspase-3
Fig. 8. Diagram summarizing the pathway of apoptosis induced by atorvastatin in hepatic stellate cells (HSCs). Atorvastatin induces
an increased phosphorylation of extracellular signal-regulated protein kinase (ERK1/2) which is followed by activation and cleavage of
Bid into truncated Bid (t-Bid). t-Bid translocates to the mitochondria leading to changes in the mitochondrial membrane permeability
(see Fig. 7), which initiates activation of procaspase-9 to caspase-9. The activated caspase-9 is released from the apoptosome and
subsequently initiates a caspase cascade involving the effector caspases such as caspase-3. Once active, this caspase cleaves various
cellular targets, ultimately leading to DNA damage and apoptosis.
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transcription factors.
Considering the importance of apoptosis occurring
in activated HSCs, these in vitro data suggest that
atorvastatin could act not only as an anti-inﬂamma-
tory agent but also as an antiﬁbrotic agent. On the
other hand, other ﬁbrogenic cells (like the resident
myoﬁbroblasts and ﬁbroblasts) are involved in liver
ﬁbrogenesis. Preliminary observations suggest that
liver myoﬁbroblasts show a different response to
atorvastatin administration with respect to apoptosis
when compared with activated HSCs.
These results suggest atorvastatin as a candidate for
further in vitro as well as in vivo study in antiﬁbrotic
strategies.
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